- Title
- NSW cannabis medicines advisory service retrospective enquiry analysis to inform clinical guidance resource development
- Creator
- Graham, Myfanwy; Eden, Edward; Maddison, Kelsey; Lago, Luise; Allingham, Samuel; Lucas, Catherine J.; Schneider, Jennifer; Martin, Jennifer H.
- Relation
- Neuropsychopharmacology Reports Vol. 45, Issue 1, no. e12498
- Publisher Link
- http://dx.doi.org/10.1002/npr2.12498
- Publisher
- John Wiley & Sons
- Resource Type
- journal article
- Date
- 2025
- Description
- Background: An innovative New South Wales government funded statewide Cannabis Medicines Advisory Service (CMAS) operated between January 2018 and June 2022. The service provided comprehensive patient-specific and evidence-based information to support health professionals in prescribing and patient care decisions. This study aimed to describe real-world data collected by CMAS. Methods: A sub-set of de-identified, patient-specific enquiries collected between January 2021 and June 2022 (n = 123/567; 21.7%) were analyzed using R version 4.2.1. Diagnosis, indication, and comorbidities were coded using Medical Dictionary for Regulatory Activities (MedDRA) terminology. Results: Most patient-specific enquiries from medical practitioners were from general practitioners (n = 103/123; 83.7%). Female (n = 53/123; 43.1%) and male (n = 59/123; 48.0%) patients were similarly represented. Sex was not specified for 8.9% (n = 11/123) of patients. The mean age of patients was 52.1 years (range <10–90). The most common three diagnoses were osteoarthritis, anxiety, and chronic pain. Indications that were most frequently reported included chronic pain, anxiety, back pain, non-neuropathic pain, and insomnia. Comedications were most commonly non-opioid and opioid analgesics and antidepressants. Most practitioners were considering prescribing a cannabidiol (CBD) product for their patient. Cannabinoid composition selection guidance provided by CMAS was predominantly (delta-9-tetrahydrocannabinol) THC:CBD ~1:1, followed by CBD-only products. CMAS was contacted by health professionals regarding the management of potential adverse events for five patients. Conclusion: The findings of this study shed light on the information medical practitioners were seeking to inform their clinical decision-making about medical cannabis and can inform the development of clinical guidance resources.
- Subject
- clinical guidance; medical cannabis; obervational study; real-world evidence; safety
- Identifier
- http://hdl.handle.net/1959.13/1516623
- Identifier
- uon:57001
- Identifier
- ISSN:2574-173X
- Rights
- © 2024 The Author(s). Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
- Language
- eng
- Full Text
- Reviewed
- Hits: 58
- Visitors: 63
- Downloads: 5
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT01 | Publisher version (open access) | 601 KB | Adobe Acrobat PDF | View Details Download |